Effectiveness of a Medifast meal replacement program on weight, body composition and cardiometabolic risk factors in overweight and obese adults: a multicenter systematic retrospective chart review study

Christopher D Coleman, Jessica R Kiel, Andrea H Mitola, Janice S Langford, Kevin N Davis, Linda M Arterburn, Christopher D Coleman, Jessica R Kiel, Andrea H Mitola, Janice S Langford, Kevin N Davis, Linda M Arterburn

Abstract

Background: Recent medical guidelines emphasize the importance of actively treating overweight and obesity with diet and lifestyle intervention to achieve ≥ 5% weight loss in a 6-month period. Commercial programs offer one approach provided there is evidence of their efficacy and safety. This study was conducted to evaluate the effectiveness of the Medifast® 4 & 2 & 1 Plan™ on weight loss, body composition and cardiometabolic risk factors in overweight and obese adults.

Methods: A systematic retrospective chart review of 310 overweight and obese clients following the Medifast 4 & 2 & 1 Plan at one of 21 Medifast Weight Control Centers® was conducted. Data were recorded electronically and key data points were independently verified. The primary endpoint was change from baseline body weight at 12 weeks. Within group paired t-tests were used to examine changes from baseline in a completers population. Differences between gender and age subgroups were examined using bivariate t-tests and mixed model regression analyses.

Results: For the primary endpoint at 12 weeks, body weight among completers (n = 185) was reduced by a mean of 10.9 ± 5.6 kg (-10.1%, p < 0.0001), and at 24 weeks (n = 81) mean weight was reduced by 16.0 ± 7.9 kg (-14.3%). At 12 and 24 weeks, 85% and 96% of those remaining on the plan, respectively, had lost ≥ 5% of their baseline body weight. Lean mass was preserved to within 5% of baseline throughout the 24 weeks, and fat mass represented ≥ 80% of the body weight lost from 12 weeks onward. Men, women, seniors (≥ 65 years), and non-seniors (<65 years) all had significant weight reductions with preservation of lean mass. Significant improvements in blood pressure, pulse and waist-to-hip ratio were observed. Mean weight regain among the subset who entered a formal maintenance phase was <2% during an average follow-up of 34 weeks. The meal plan was well tolerated, and program adherence was >85%.

Conclusions: The 4 & 2 & 1 Plan used at Medifast Weight Control Centers was effective for weight loss, preservation of lean mass and improvement in cardiometabolic risk factors. The plan was generally well tolerated in a broad population of overweight and obese adults. #NCT02150837.

Figures

Fig. 1
Fig. 1
Flow diagram. Chart disposition at week 12 (primary endpoint), week 24 and Final Visit. The Completers population included all individuals that had weight data within the specified visit window. Final Visit represents an individual’s last visit to the MWCC while following the 4 & 2 & 1 Plan. The time of the Final Visit varies by individual, depending on when they discontinued the 4 & 2 & 1 Plan
Fig. 2
Fig. 2
Percent change from baseline body weight. Mean (±SD) for the Completers population which included all individuals with weight data at the given visit; sample sizes are designated below the graph. Intention-to-Treat Last Observation Carried Forward (ITT LOCF) values are also shown for 12 and 24-week visits. Final Visit represents an individual’s last visit to the MWCC while on the 4 & 2 & 1 Plan. Absolute weight changes in kg are shown below the graph. Within group changes from baseline body weight using Wilcoxon signed-rank tests are shown: * p < 0.0001
Fig. 3
Fig. 3
Proportion of individuals with at least 5 % and at least 10 % reduction in baseline body weight. Analysis of the Completers population which included all individuals with weight data at the given visit; sample sizes are designated below the graph. Final Visit represents an individual’s last visit to the MWCC while on the 4 & 2 & 1 Plan
Fig. 4
Fig. 4
Change from baseline body weight, lean body mass and body fat mass. Mean (±SD) for the Completers population which included all individuals with weight data at the given visit; sample sizes are designated below the graph. Within group changes from baseline using Wilcoxon signed-rank tests are shown: * p < 0.0001
Fig. 5
Fig. 5
Percent change from baseline in (a) body weight and (b) lean and fat mass by gender. Mean (±SD) for the Completers population which included all individuals with weight data at the given visit; sample sizes are designated below the graph. Final Visit represents an individual’s last visit to the MWCC while on the 4 & 2 & 1 Plan. Significance levels for all within group changes from baseline were p < 0.0001 for body weight and fat mass and p < 0.01 lean mass (not shown). Significance levels for between group comparisons using bivariate t-tests at each time point are shown: *p < 0.05; **p < 0.01; ***p < 0.0001
Fig. 6
Fig. 6
Percent change from baseline (a) body weight and (b) lean and fat mass by age group. Mean (±SD) for the Completers population grouped by age (<65 and ≥65 years). Completers included all individuals with weight data at the given visit; sample sizes are designated below the graph. Final Visit represents an individual’s last visit to the MWCC while on the 4 & 2 & 1 Plan. Significance levels for all within group changes from baseline were p < 0.0001 for body weight, p ≤ 0.002 for fat mass and p ≤ 0.05 for lean mass (not shown). Significance levels for between group comparisons using bivariate t-tests at each time point are shown: *p < 0.05; **p < 0.01; ***p < 0.0001

References

    1. Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al. AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Obesity Society. Circulation. 2013;128:1–69.
    1. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011–2012. JAMA. 2014;311:806–814. doi: 10.1001/jama.2014.732.
    1. United States. Public Health Service. Office of the Surgeon General, United States. Office of Disease Prevention and Health Promotion. Centers for Disease Control and Prevention (U.S.) National Institutes of Health (U.S.) The Surgeon General’s Call to Action to Prevent and Decrease Overweight and Obesity. Washington, DC: U.S. Dept. of Health and Human Services, Public Health Service, For sale by the Supt. of Docs., U.S. G.P.O; 2001.
    1. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999–2008. JAMA. 2010;303:235–241. doi: 10.1001/jama.2009.2014.
    1. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity in the United States, 2009–2010. NCHS Data Brief. 2012;82:1–8.
    1. Pagoto SL, Schneider KL, Oleski JL, Luciani JM, Bodenlos JS, Whited MC. Male inclusion in randomized controlled trials of lifestyle weight loss interventions. Obesity (Silver Spring) 2012;20:1234–1239. doi: 10.1038/oby.2011.140.
    1. Waters DL, Ward AL, Villareal DT. Weight loss in obese adults 65 years and older: a review of the controversy. Exp Gerontol. 2013;48:1054–61.
    1. Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE. Adult weight change and risk of postmenopausal breast cancer. JAMA. 2006;296:193–201. doi: 10.1001/jama.296.2.193.
    1. Parker ED, Folsom AR. Intentional weight loss and incidence of obesity-related cancers: the Iowa Women’s Health Study. Int J Obes Relat Metab Disord. 2003;27:1447–1452. doi: 10.1038/sj.ijo.0802437.
    1. Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34:1481–6.
    1. Lau DC, Teoh H. Benefits of modest weight loss on the management of type 2 diabetes mellitus. Can J Diabetes. 2013;37:128–134. doi: 10.1016/j.jcjd.2013.03.023.
    1. Ochner CN, Tsai AG, Kushner RF, Wadden TA. Treating obesity seriously: when recommendations for lifestyle change confront biological adaptations. Lancet Diabetes Endocrinol. 2015;3:232–234. doi: 10.1016/S2213-8587(15)00009-1.
    1. American College of Cardiology/American Heart Association Task Force on Practice Guidelines OEP Expert panel report: guidelines (2013) for the management of overweight and obesity in adults. Obesity (Silver Spring) 2014;22(Suppl 2):S41–410.
    1. Heymsfield SB, van Mierlo CA, van der Knaap HC, Heo M, Frier HI. Weight management using a meal replacement strategy: meta and pooling analysis from six studies. Int J Obes Relat Metab Disord. 2003;27:537–549. doi: 10.1038/sj.ijo.0802258.
    1. American Dietetic Association Position of the American Dietetic Association: weight management. Journal of the American Dietetic Association. 2009;109:330–346. doi: 10.1016/j.jada.2008.11.041.
    1. Coleman C, Kiel J, Hanlon-Mitola A, Sonzone C, Fuller N, Davis LM. Use of the Medifast meal replacement program for weight loss in overweight and obese clients: a retrospective chart review of three Medifast Weight Control Centers (MWCC) Food and Nutrition Sciences. 2012;03:1433–1444. doi: 10.4236/fns.2012.310187.
    1. Davis LM, Coleman C, Kiel J, Rampolla J, Hutchisen T, Ford L, et al. Efficacy of a meal replacement diet plan compared to a food-based diet plan after a period of weight loss and weight maintenance: a randomized controlled trial. Nutr J. 2010;9:11.
    1. Shikany JM, Thomas AS, Beasley TM, Lewis CE, Allison DB. Randomized controlled trial of the Medifast 5 & 1 Plan for weight loss. Int J Obes (Lond) 2013;37:1571–1578. doi: 10.1038/ijo.2013.43.
    1. Vassar M, Holzmann M. The retrospective chart review: important methodological considerations. Journal of Educational Evaltuation for Health Professions. 2013;10:1–7. doi: 10.3352/jeehp.2013.10.1.
    1. Karelis AD, Chamberland G, Aubertin-Leheudre M, Duval C, Ecological mobility in A, Parkinson g Validation of a portable bioelectrical impedance analyzer for the assessment of body composition. Appl Physiol Nutr Metab. 2013;38:27–32. doi: 10.1139/apnm-2012-0129.
    1. Heymsfield SB. Meal replacements and energy balance. Physiol Behav. 2010;100:90–94. doi: 10.1016/j.physbeh.2010.02.010.
    1. Ashley JM, St Jeor ST, Perumean-Chaney S, Schrage J, Bovee V. Meal replacements in weight intervention. Obes Res. 2001;9(Suppl 4):312S–320S. doi: 10.1038/oby.2001.136.
    1. Hannum SM, Carson L, Evans EM, Canene KA, Petr EL, Bui L, et al. Use of portion-controlled entrees enhances weight loss in women. Obes Res. 2004;12:538–46.
    1. Bhogal MS, Langford R. Gender differences in weight loss: evidence from a NHS weight management service. Public Health. 2014;128:811–813. doi: 10.1016/j.puhe.2014.06.019.
    1. Tsai SA, Lv N, Xiao L, Ma J. Gender differences in weight-related attitudes and behaviors among overweight and obese adults in the United States. Am J Mens Health. 2015; pii: 1557988314567223. [Epub ahead of print].
    1. Dixon JB, Lambert EA, Grima M, Rice T, Lambert GW, Straznicky NE. Fat-free mass loss generated with weight loss in overweight and obese adults: what may we expect? Diabetes Obes Metab. 2015;17:91–93. doi: 10.1111/dom.12389.
    1. Heymsfield SB, Gonzalez MC, Shen W, Redman L, Thomas D. Weight loss composition is one-fourth fat-free mass: a critical review and critique of this widely cited rule. Obes Rev. 2014;15:310–321. doi: 10.1111/obr.12143.
    1. Chaston TB, Dixon JB, O’Brien PE. Changes in fat-free mass during significant weight loss: a systematic review. Int J Obes (Lond) 2007;31:743–750.
    1. Tang M, Leidy HJ, Campbell WW. Regional, but not total, body composition changes in overweight and obese adults consuming a higher protein, energy-restricted diet are sex specific. Nutr Res. 2013;33:629–635. doi: 10.1016/j.nutres.2013.05.012.
    1. Pasiakos SM, Margolis LM, Orr JS. Optimized dietary strategies to protect skeletal muscle mass during periods of unavoidable energy deficit. FASEB J. 2015;29:1136–1142. doi: 10.1096/fj.14-266890.
    1. Krieger JW, Sitren HS, Daniels MJ, Langkamp-Henken B. Effects of variation in protein and carbohydrate intake on body mass and composition during energy restriction: a meta-regression. Am J Clin Nutr. 2006;83:260–274.
    1. Weijs PJ, Wolfe RR. Exploration of the protein requirement during weight loss in obese older adults. Clin Nutr. 2015. doi:10.1016/j.clnu.2015.02.016.
    1. Beavers KM, Gordon MM, Easter L, Beavers DP, Hairston KG, Nicklas BJ, et al. Effect of protein source during weight loss on body composition, cardiometabolic risk and physical performance in abdominally obese, older adults: a pilot feeding study. J Nutr Health Aging. 2015;19:87–95.
    1. Wirth A, Steinmetz B. Gender differences in changes in subcutaneous and intra-abdominal fat during weight reduction: an ultrasound study. Obes Res. 1998;6:393–399. doi: 10.1002/j.1550-8528.1998.tb00370.x.
    1. McInnes GT. Lowering blood pressure for cardiovascular risk reduction. J Hypertens Suppl. 2005;23:S3–8. doi: 10.1097/01.hjh.0000165622.34192.fd.
    1. Wadden TA, West DS, Neiberg RH, Wing RR, Ryan DH, Johnson KC, et al. One-year weight losses in the Look AHEAD study: factors associated with success. Obesity (Silver Spring). 2009;17:713–22.
    1. Wadden TA, Neiberg RH, Wing RR, Clark JM, Delahanty LM, Hill JO, et al. Four-year weight losses in the Look AHEAD study: factors associated with long-term success. Obesity (Silver Spring). 2011;19:1987–98.
    1. Wing RR, Jeffery RW. Food provision as a strategy to promote weight loss. Obes Res. 2001;9(Suppl 4):271S–275S. doi: 10.1038/oby.2001.130.
    1. Poston WS, Haddock CK, Pinkston MM, Pace P, Karakoc ND, Reeves RS, et al. Weight loss with meal replacement and meal replacement plus snacks: a randomized trial. Int J Obes (Lond). 2005;29:1107–14.
    1. Finley CE, Barlow CE, Greenway FL, Rock CL, Rolls BJ, Blair SN. Retention rates and weight loss in a commercial weight loss program. Int J Obes (Lond) 2007;31:292–298. doi: 10.1038/sj.ijo.0803395.
    1. Gudzune KA, Doshi RS, Mehta AK, Chaudhry ZW, Jacobs DK, Vakil RM, et al. Efficacy of commercial weight-loss programs: an updated systematic review. Ann Intern Med. 2015;162:501–12.
    1. Heshka S, Heymsfield S. International Textbook of Obesity. Chichester: Wiley; 2001. Obesity and Gallstones; pp. 399–409.
    1. Njeze GE. Gallstones. Nigeria: Nigerian Journal of Surgery; 2013.
    1. Festi D, Colecchia A, Larocca A, Villanova N, Mazzella G, Petroni ML, et al. Review: low caloric intake and gall-bladder motor function. Aliment Pharmacol Ther. 2000;14 Suppl 2:51–3.
    1. Vezina WC, Grace DM, Hutton LC, Alfieri MH, Colby PR, Downey DB, et al. Similarity in gallstone formation from 900 kcal/day diets containing 16 g vs 30 g of daily fat: evidence that fat restriction is not the main culprit of cholelithiasis during rapid weight reduction. Dig Dis Sci. 1998;43:554–61.
    1. Everhart JE. Contributions of obesity and weight loss to gallstone disease. Ann Intern Med. 1993;119:1029–1035. doi: 10.7326/0003-4819-119-10-199311150-00010.
    1. Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363:245–56.
    1. Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. The Lancet. 2011;377:1341–52.
    1. Smith SR, Prosser WA, Donahue DJ, Morgan ME, Anderson CM, Shanahan WR, et al. Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women. Obesity (Silver Spring). 2009;17:494–503.

Source: PubMed

3
Subskrybuj